Krzysztof Simon

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Scott L. Friedman, Vlad Ratziu, Stephen A. Harrison et al. · Hepatology · 2017 · 658 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

Erik H.C.J. Buster, Hajo J. Flink, Yılmaz Çakaloğlu et al. · Gastroenterology · 2008 · 396 citations · Full text

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +2

Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels†

Vincent Rijckborst, Bettina E. Hansen, Yılmaz Çakaloğlu et al. · Hepatology · 2010 · 241 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)

Willem Pieter Brouwer, Qing Xie, Milan J. Sonneveld et al. · Hepatology · 2014 · 165 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17